◎ Sugi Atlas

Atlas / Drug / Ruxolitinib

Ruxolitinib

drug
On this page

Also known as INC-424INC424INCB-018424INCB-18424INCB018424Jakavis-S-ruxolitinibJAKAFIRUXOLITINIB PHOSPHATEINCB-018424 SALTINCB018424(R)-RUXOLITINIBINCB018424 (RUXOLITINIB)RUXOLITINIB (INCB018424)(R)-RUXOLITINIBINCB18424RuxolitinibJakafiRuxolitinib phosphateÊRuxolitinib phosphateÂ

Summary

Ruxolitinib (CHEMBL1789941) is an approved small-molecule antineoplastic agent (ATC D11AH09) targeting JAK1, JAK2, and JAK3; indicated across 66 conditions including neoplasm and primary myelofibrosis; with CIViC clinical evidence for 13 variant-indication associations (e.g. PCM1::JAK2 Fusion OR BCR::JAK2 Fusion in myeloid neoplasm).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: D11AH09 (+1 more)
  • Targets: 4 (JAK1, JAK2, JAK3…)
  • Indications: 66 conditions
  • Clinical trials: 373
  • Precision-oncology evidence (CIViC): 13 variant–indication associations
  • Chemistry: 306.4 Da · C17H18N6

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1789941
NameRuxolitinib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID25126798
ChEBICHEBI:66919
ATCD11AH09, L01EJ01
Molecular formulaC17H18N6
Molecular weight306.4
InChIKeyHFNKQEVNSGCOJV-OAHLLOKOSA-N

SMILES: C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

IUPAC name: (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile

ChEBI definition: A pyrazole substituted at position 1 by a 2-cyano-1-cyclopentylethyl group and at position 3 by a pyrrolo[2,3-d]pyrimidin-4-yl group. Used as the phosphate salt for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.

Pharmacological roles (ChEBI): antineoplastic agent, EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor.

Also known as: INC-424, INC424, INCB-018424, INCB-18424, INCB018424, Jakavi, Ruxolitinib, s-, S-ruxolitinib, JAKAFI, RUXOLITINIB PHOSPHATE, INCB-018424 SALT

Parent form; salt/anhydrous children: CHEMBL1795071, CHEMBL4594381, CHEMBL4594382

Patent coverage: 4,564 distinct patent families (11,547 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 10,593 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
JAK1Janus kinase 1Inhibition10.052.8%P23458
JAK2Janus kinase 2Inhibition8.050.7%O60674
JAK3Janus kinase 3Inhibition6.310.6%P52333
TYK2tyrosine kinase 2Inhibition7.520.8%P29597

Broader ChEMBL bioactivity targets: 142 (assay-derived). Sample: Leucine-rich repeat serine/threonine-protein kinase 2, Rhodopsin kinase GRK7, Serine/threonine-protein kinase TAO2, Serine/threonine-protein kinase/endoribonuclease IRE1, Serine/threonine-protein kinase OSR1, STE20/SPS1-related proline-alanine-rich protein kinase, Mitogen-activated protein kinase kinase kinase 15, Microtubule-associated serine/threonine-protein kinase 1, Serine/threonine-protein kinase SBK1, Tyrosine-protein kinase JAK2.

Bioactivity

ChEMBL activities: 353 potent at pChembl ≥ 5 of 362 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
JAK210.44IC500.04nMCHEMBL_ACT_25701597
JAK210.44IC500.04nMCHEMBL_ACT_25938456
JAK210.44Kd0.04nMCHEMBL_ACT_7571811
JAK210.25IC500.06nMCHEMBL_ACT_18141618
JAK210.25IC500.06nMCHEMBL_ACT_18665620
JAK110.05Ki0.09nMCHEMBL_ACT_12138162
JAK110.05IC500.09nMCHEMBL_ACT_25701589
JAK110.05IC500.09nMCHEMBL_ACT_25938455
JAK210Ki0.1nMCHEMBL_ACT_12069216
JAK210Ki0.1nMCHEMBL_ACT_13317341
JAK29.92IC500.12nMCHEMBL_ACT_16515204
JAK19.7Ki0.2nMCHEMBL_ACT_12069217
JAK19.7Ki0.2nMCHEMBL_ACT_13317342
JAK29.7IC500.2nMCHEMBL_ACT_15112131
JAK29.62Ki0.24nMCHEMBL_ACT_12138165
TYK29.4IC500.4nMCHEMBL_ACT_13901940
JAK29.4IC500.4nMCHEMBL_ACT_22812634
TYK29.4IC500.4nMCHEMBL_ACT_25701608
JAK19.37IC500.43nMCHEMBL_ACT_16515210
TYK29.3Ki0.5nMCHEMBL_ACT_12069214
TYK29.3Ki0.5nMCHEMBL_ACT_13317339
TYK29.3Ki0.5nMCHEMBL_ACT_13317472
TYK29.26Ki0.55nMCHEMBL_ACT_12138160
JAK19.22IC500.6nMCHEMBL_ACT_13902022
JAK29.22IC500.6nMCHEMBL_ACT_18992766
JAK29.15IC500.7nMCHEMBL_ACT_13901996
TYK29.14IC500.72nMCHEMBL_ACT_16515192
JAK19.1IC500.8nMCHEMBL_ACT_13282600
JAK29.1Kd0.8nMCHEMBL_ACT_25839811
TYK29.05Kd0.9nMCHEMBL_ACT_7571747

Target pathways

Aggregated over 4 target gene(s): JAK1, JAK2, JAK3, TYK2.

Top Reactome pathways

86 total, by targets touching each:

PathwayTargetsGenes
Interleukin-4 and Interleukin-13 signaling4JAK1, JAK2, JAK3, TYK2
Interleukin-20 family signaling4JAK1, JAK2, JAK3, TYK2
Potential therapeutics for SARS4JAK1, JAK2, JAK3, TYK2
Interleukin-6 signaling3JAK1, JAK2, TYK2
MAPK3 (ERK1) activation3JAK1, JAK2, TYK2
MAPK1 (ERK2) activation3JAK1, JAK2, TYK2
Cytokine Signaling in Immune system3JAK1, JAK2, JAK3
Signal Transduction3JAK1, JAK2, JAK3
Disease3JAK1, JAK2, JAK3
Immune System3JAK1, JAK2, JAK3
Signaling by Interleukins3JAK1, JAK2, JAK3
Interleukin-2 family signaling3JAK1, JAK2, JAK3
Interleukin-3, Interleukin-5 and GM-CSF signaling3JAK1, JAK2, JAK3
Infectious disease3JAK1, JAK2, JAK3
RAF/MAP kinase cascade3JAK1, JAK2, JAK3
MAPK family signaling cascades3JAK1, JAK2, JAK3
MAPK1/MAPK3 signaling3JAK1, JAK2, JAK3
IL-6-type cytokine receptor ligand interactions3JAK1, JAK2, TYK2
Interleukin-35 Signalling3JAK1, JAK2, TYK2
Interleukin-12 signaling3JAK1, JAK2, TYK2
Interleukin-27 signaling3JAK1, JAK2, TYK2
Interleukin receptor SHC signaling3JAK1, JAK2, JAK3
Signaling by CSF3 (G-CSF)3JAK1, JAK2, TYK2
SARS-CoV Infections3JAK1, JAK2, JAK3
Inactivation of CSF3 (G-CSF) signaling3JAK1, JAK2, TYK2
Viral Infection Pathways3JAK1, JAK2, JAK3
Activation of STAT3 by cadherin engagement3JAK1, JAK2, TYK2
RAF-independent MAPK1/3 activation2JAK1, JAK2
Interleukin-7 signaling2JAK1, JAK3
Interleukin-12 family signaling2JAK1, JAK2

Dominant GO biological processes

GO termTargets
protein phosphorylation4
cell surface receptor signaling pathway via JAK-STAT4
cytokine-mediated signaling pathway4
cell differentiation4
intracellular signal transduction4
growth hormone receptor signaling pathway via JAK-STAT4
regulation of cell-cell adhesion4
type II interferon-mediated signaling pathway3
cellular response to virus3
regulation of receptor signaling pathway via JAK-STAT3
regulation of alpha-beta T cell activation3
interleukin-15-mediated signaling pathway2
interleukin-4-mediated signaling pathway2
interleukin-2-mediated signaling pathway2
interleukin-7-mediated signaling pathway2

Indications & clinical

Indications

66 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
primary myelofibrosis3MONDO:0009692EFO:0002430
graft versus host disease3MONDO:0013730EFO:0004599
vitiligo3MONDO:0008661EFO:0004208
essential thrombocythemia3MONDO:0005029EFO:0000479
acquired polycythemia vera3MONDO:0009891EFO:0002429
atopic eczema3MONDO:0004980EFO:0000274
exocrine pancreatic carcinoma3MONDO:0005192EFO:0002618
severe acute respiratory syndrome3MONDO:0005091EFO:0000694
macrophage activation syndrome3MONDO:0015545EFO:1001806
prurigo3MONDO:0021739MONDO:0021739
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
leukemia2MONDO:0005059EFO:0000565
Hodgkins lymphoma2MONDO:0004952EFO:0000183
breast carcinoma2MONDO:0004989EFO:0000305
psoriasis2MONDO:0005083EFO:0000676
HIV infectious disease2MONDO:0005109EFO:0000764
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
alopecia areata2MONDO:0005340EFO:0004192
rheumatoid arthritis2MONDO:0008383EFO:0000685
acute lymphoblastic leukemia2MONDO:0004967EFO:0000220
acute myeloid leukemia2MONDO:0018874EFO:0000222
chronic myeloid leukemia2MONDO:0011996EFO:0000339
lymphoma2MONDO:0005062EFO:0000574
plasma cell myeloma2MONDO:0009693EFO:0001378
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
inflammatory breast carcinoma2MONDO:0006804EFO:1000984
colorectal carcinoma2MONDO:0024331EFO:1001951
lymphoid neoplasm2MONDO:0005157EFO:0001642
lichen planus2MONDO:0006572EFO:1000726
hypereosinophilic syndrome2MONDO:0015691EFO:1001467
breast neoplasm2MONDO:0021100MONDO:0007254
hidradenitis suppurativa2MONDO:0006559EFO:1000710
necrobiosis lipoidica2MONDO:0006583EFO:1000738
bronchiolitis obliterans syndrome2MONDO:0015265EFO:0007183
discoid lupus erythematosus2MONDO:0019558MONDO:0019558
beta thalassemia2MONDO:0019402MONDO:0016486
anemia2MONDO:0002280EFO:0004272
lichen disease2MONDO:0006570EFO:1000724
seborrheic dermatitis2MONDO:0006608EFO:1000764
histiocytosis2MONDO:0002637HP:0100727
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
T-cell acute lymphoblastic leukemia1MONDO:0004963EFO:0000209
glioblastoma1MONDO:0018177EFO:0000519
lung neoplasm1MONDO:0021117MONDO:0008903
pneumonia1MONDO:0005249EFO:0003106
dermatitis1MONDO:0002406MONDO:0002406
neuromyelitis optica1MONDO:0019100EFO:0004256
paraganglioma1MONDO:0000448EFO:1000453
uveal melanoma1MONDO:0006486EFO:1000616
pancreatic ductal adenocarcinoma1MONDO:0005184MONDO:0005184
malignant atrophic papulosis1MONDO:0011208MONDO:0011208

13 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 373.

Phase distribution

PhaseTrials
PHASE2154
PHASE162
PHASE1/PHASE255
PHASE350
Not specified29
PHASE415
PHASE2/PHASE35
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02386800PHASE4ACTIVE_NOT_RECRUITINGCINC424A2X01B Rollover Protocol
NCT06364319PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
NCT06462469PHASE4RECRUITINGStudy of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
NCT06824103PHASE4RECRUITINGStudy of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
NCT07101588PHASE4RECRUITINGRuxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
NCT07352566PHASE4NOT_YET_RECRUITINGUtilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07498205PHASE4NOT_YET_RECRUITINGComparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
NCT01558739PHASE4COMPLETEDExploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
NCT04446806PHASE4UNKNOWNPrevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
NCT04999878PHASE4UNKNOWNA Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
NCT05021276PHASE4UNKNOWNBasiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
NCT05447260PHASE4UNKNOWNA New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis
NCT05491304PHASE4UNKNOWNCytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
NCT05696392PHASE4TERMINATEDThe Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
NCT07368673PHASE4COMPLETEDComparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial
NCT03117751PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTotal Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT04116502PHASE3RECRUITINGMITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT04468984PHASE3ACTIVE_NOT_RECRUITINGStudy of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
NCT04562389PHASE3ACTIVE_NOT_RECRUITINGStudy of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04603495PHASE3ACTIVE_NOT_RECRUITINGPhase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT06079879PHASE3RECRUITINGA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06479135PHASE3RECRUITINGStudy of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06548360PHASE3RECRUITINGA Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06615050PHASE3RECRUITINGA Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
NCT06804811PHASE3RECRUITINGA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06832618PHASE3RECRUITINGA Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06958211PHASE3RECRUITINGStudy to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06959225PHASE3RECRUITINGStudy to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT07297914PHASE2/PHASE3NOT_YET_RECRUITINGFramework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
NCT07317700PHASE3RECRUITINGA Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
NCT07357727PHASE3RECRUITINGA Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07366801PHASE2/PHASE3RECRUITINGCo-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
NCT07588945PHASE3NOT_YET_RECRUITINGdaGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT
NCT07595939PHASE3NOT_YET_RECRUITINGEfficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo
NCT00934544PHASE3COMPLETEDControlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
NCT00952289PHASE3COMPLETEDCOntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
NCT01243944PHASE3COMPLETEDStudy of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
NCT01493414PHASE3COMPLETEDINC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.
NCT01632904PHASE3COMPLETEDRandomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
NCT01969838PHASE3COMPLETEDMomelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

Clinical evidence (CIViC)

Variant × indication × effect (13 predictive associations from 14 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
PCM1::JAK2 Fusion OR BCR::JAK2 FusionMyeloid NeoplasmSensitivity/ResponseRuxolitinibCIViC BEID11325
CSF3R T618IChronic Neutrophilic LeukemiaSensitivity/ResponseRuxolitinibCIViC CEID6381 +1
GOLGA5::JAK2 FusionB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeSensitivity/ResponseRuxolitinibCIViC CEID7007
JAK1 OVEREXPRESSIONSarcomaSensitivity/ResponseRuxolitinibCIViC CEID7852
JAK2 F694LChildhood B-cell Acute Lymphoblastic LeukemiaSensitivity/ResponseRuxolitinibCIViC CEID7021
SSBP2::JAK2 FusionB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeSensitivity/ResponseRuxolitinibCIViC CEID7257
VHL R200W (c.598C>T)Chuvash PolycythemiaSensitivity/ResponseRuxolitinibCIViC CEID1608
IGH::CRLF2 FusionAcute Lymphoblastic LeukemiaSensitivity/ResponseRuxolitinibCIViC DEID8540
JAK1 A1086SHepatocellular CarcinomaSensitivity/ResponseRuxolitinibCIViC DEID10058
JAK1 E483DHepatocellular CarcinomaSensitivity/ResponseRuxolitinibCIViC DEID10057
JAK1 N451SHepatocellular CarcinomaSensitivity/ResponseRuxolitinibCIViC DEID10056
JAK1 S646FB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeSensitivity/ResponseRuxolitinibCIViC DEID7957
JAK1 S703IHepatocellular CarcinomaSensitivity/ResponseRuxolitinibCIViC DEID1900

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

126 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
DEUCRAVACITINIBChEMBL + PubChemPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
PazopanibChEMBL + PubChemPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
RITLECITINIBChEMBL + PubChemPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
ABROCITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
BARICITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
FEDRATINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
FILGOTINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
MIDOSTAURINChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
MOMELOTINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
NINTEDANIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
PACRITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
PEFICITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
SUNITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
TOFACITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
UPADACITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3, TYK2
BREPOCITINIBChEMBLPhase 3JAK1, JAK2, JAK3, TYK2
DELGOCITINIBChEMBLPhase 3JAK1, JAK2, JAK3, TYK2
DOVITINIBChEMBLPhase 3JAK1, JAK2, JAK3, TYK2
ITACITINIBChEMBLPhase 3JAK1, JAK2, JAK3, TYK2
LESTAURTINIBChEMBLPhase 3JAK1, JAK2, JAK3, TYK2
AT-9283ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
ATINVICITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
AZD-1480ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
BMS-911543ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
CC-401ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
CERDULATINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
DECERNOTINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
GANDOTINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
GOLIDOCITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
GUSACITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
IFIDANCITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
IZENCITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
NEZULCITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
NS-018ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
OCLACITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
R-406ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
ROPSACITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
SOLCITINIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
SU-014813ChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
TOZASERTIBChEMBLPhase 2JAK1, JAK2, JAK3, TYK2
AfatinibPubChemApprovedJAK1, JAK2, JAK3, TYK2
GefitinibPubChemApprovedJAK1, JAK2, JAK3, TYK2
IdelalisibPubChemApprovedJAK1, JAK2, JAK3, TYK2
SelumetinibPubChemApprovedJAK1, JAK2, JAK3, TYK2
dacomitinibChEMBL + PubChemPhase 4 (approved)JAK1, JAK3, TYK2
IMATINIBChEMBL + PubChemPhase 4 (approved)JAK1, JAK2, TYK2
AXITINIBChEMBLPhase 4 (approved)JAK2, JAK3, TYK2
BOSUTINIBChEMBLPhase 4 (approved)JAK2, JAK3, TYK2
CERITINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3
DASATINIBChEMBLPhase 4 (approved)JAK2, JAK3, TYK2
ENTRECTINIBChEMBLPhase 4 (approved)JAK1, JAK2, JAK3
ERLOTINIBChEMBLPhase 4 (approved)JAK2, JAK3, TYK2
ABIVERTINIBChEMBLPhase 3JAK1, JAK2, JAK3
ALVOCIDIBChEMBLPhase 3JAK2, JAK3, TYK2
DEFACTINIBChEMBLPhase 3JAK2, JAK3, TYK2
BMS-919373ChEMBLPhase 2JAK2, JAK3, TYK2
CENISERTIBChEMBLPhase 2JAK2, JAK3, TYK2
LONDAMOCITINIBChEMBLPhase 2JAK1, JAK2, TYK2
belumosudilPubChemApprovedJAK2, JAK3, TYK2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot